Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans


Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited arrhythmia syndrome in which drug therapy is often ineffective. We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor–mediated Ca2+ release and thereby directly targeting the underlying molecular defect. Flecainide completely prevented CPVT in two human subjects who had remained highly symptomatic on conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy for CPVT.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Flecainide inhibits RyR2 Ca2+ release channels, reduces spontaneous Ca2+ release events and triggered beats and prevents ventricular tachycardia in a CPVT mouse model.
Figure 2: Flecainide treatment prevents exercise-induced ventricular arrhythmia in two subjects with CPVT refractory to conventional drug therapy.


  1. Leenhardt, A. et al. Circulation 91, 1512–1519 (1995).

    CAS  Article  Google Scholar 

  2. Mohamed, U., Gollob, M.H., Gow, R.M. & Krahn, A.D. Heart Rhythm 3, 1486–1489 (2006).

    Article  Google Scholar 

  3. Pizzale, S., Gollob, M.H., Gow, R. & Birnie, D.H. J. Cardiovasc. Electrophysiol. 9, 1319–1321 (2008).

    Article  Google Scholar 

  4. Wilde, A.A. et al. N. Engl. J. Med. 358, 2024–2029 (2008).

    CAS  Article  Google Scholar 

  5. Robinson, M., Park, J. & Raff, G. Heart Rhythm 4 Suppl, S100 (2007).

    Google Scholar 

  6. Priori, S.G. et al. Circulation 103, 196–200 (2001).

    CAS  Article  Google Scholar 

  7. Lahat, H. et al. Am. J. Hum. Genet. 69, 1378–1384 (2001).

    CAS  Article  Google Scholar 

  8. Jiang, D. et al. Proc. Natl. Acad. Sci. USA 101, 13062–13067 (2004).

    CAS  Article  Google Scholar 

  9. di Barletta, M.R. et al. Circulation 114, 1012–1019 (2006).

    CAS  Article  Google Scholar 

  10. Knollmann, B.C. et al. J. Clin. Invest. 116, 2510–2520 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Cerrone, M. et al. Circ. Res. 101, 1039–1048 (2007).

    CAS  Article  Google Scholar 

  12. Venetucci, L.A., Trafford, A.W., Diaz, M.E., O'Neill, S.C. & Eisner, D.A. Circ. Res. 98, 1299–1305 (2006).

    CAS  Article  Google Scholar 

  13. Gyorke, S., Lukyanenko, V. & Gyorke, I. J. Physiol. (Lond.) 500, 297–309 (1997).

    CAS  Article  Google Scholar 

  14. Shoshan-Barmatz, V. & Zchut, S. J. Membr. Biol. 133, 171–181 (1993).

    CAS  Article  Google Scholar 

  15. Marban, E., Robinson, S.W. & Wier, W.G. J. Clin. Invest. 78, 1185–1192 (1986).

    CAS  Article  Google Scholar 

  16. Rosen, M.R. & Danilo, P. Jr. Circ. Res. 46, 117–124 (1980).

    CAS  Article  Google Scholar 

  17. De Rosa, G. et al. Pediatr. Emerg. Care 20, 175–177 (2004).

    Article  Google Scholar 

  18. Postma, A.V. et al. Circ. Res. 91, e21–e26 (2002).

    CAS  Article  Google Scholar 

Download references


We thank S. Huke and S. Kim for their assistance with the data analysis and the preparation of figures, P. Johnson for his assistance with the single-channel recording and N. Masalha and S.A. Clur for their assistance in patient care and management. This work was supported in part by the US National Institutes of Health grants HL88635 and HL71670 (to B.C.K.) and HL49989 (to D.M.R.), by the American Heart Association Established Investigator Award 0840071N (to B.C.K.), by the Australian Research Council grant DP0557780 (to D.R.L.), by an infrastructure grant from New South Wales Health through Hunter Medical Research Institute (to D.R.L.), by the Leducq Foundation grant 05CVD01 (to A.A.M.W. and D.M.R.) and by the Alberta Heart and Stroke Foundation Chair in Cardiovascular Medicine (to H.J.D.).

Author information

Authors and Affiliations



H.W. and H.S.H. conducted and analyzed the in vivo mouse ECG experiments, N.C. and H.S.H. conducted and analyzed the isolated myocyte experiments, D.L. conducted and analyzed the RyR2 single-channel experiments, A.A.M.W. conducted and analyzed the human studies, S.S.D. analyzed the flecainide concentrations, D.E.R. and H.J.D. provided the ECG telemetry analysis software, H.W. and N.C. wrote the initial draft of the manuscript, D.M.R. edited the manuscript, and B.C.K. designed and supervised the overall project, and prepared the final manuscript and figures.

Corresponding author

Correspondence to Björn C Knollmann.

Supplementary information

Supplementary Text and Figures

Supplementary Figs. 1–5 and Supplementary Methods (PDF 495 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Watanabe, H., Chopra, N., Laver, D. et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15, 380–383 (2009).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing